What is the recommended treatment for a patient experiencing migraines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Migraine Treatment Recommendations

For acute migraine treatment, start with NSAIDs (ibuprofen 400-800 mg, naproxen 500-825 mg, or aspirin 1000 mg) for mild-to-moderate attacks, and use triptans (sumatriptan 50-100 mg, rizatriptan 10 mg, or zolmitriptan) for moderate-to-severe attacks or when NSAIDs fail. 1

Acute Treatment Algorithm

Mild-to-Moderate Migraine

  • First-line: NSAIDs are the initial treatment of choice 1
    • Ibuprofen 400-800 mg 1
    • Naproxen sodium 500-825 mg 1
    • Aspirin 1000 mg 1
    • Combination: Aspirin + acetaminophen + caffeine 1
  • Take medication early in the attack while pain is still mild for maximum effectiveness 1
  • If NSAIDs fail after 2 hours, escalate to a triptan 1

Moderate-to-Severe Migraine

  • First-line: Triptans are the primary treatment 1
    • Oral options: sumatriptan 50-100 mg, rizatriptan 10 mg, naratriptan, or zolmitriptan 1
    • Combination therapy (triptan + NSAID) is superior to either agent alone and represents the strongest recommendation 1
    • Example: Sumatriptan 50-100 mg PLUS naproxen sodium 500 mg provides 130 more patients per 1000 achieving sustained pain relief at 48 hours compared to either drug alone 1

Route Selection Based on Symptoms

  • Oral route: Use when nausea is absent or mild 1
  • Non-oral routes: Required when significant nausea or vomiting is present 1, 2
    • Subcutaneous sumatriptan 6 mg: Most effective option with 70-80% achieving relief within 1 hour and 59% pain-free by 2 hours 1, 3
    • Intranasal sumatriptan 5-20 mg 1
    • Rectal formulations 2

Add Antiemetic Therapy

  • Metoclopramide 10 mg IV/oral provides both antiemetic effects and direct analgesic benefit through central dopamine receptor antagonism 1
  • Prochlorperazine 10 mg IV is equally effective for headache pain and nausea 1
  • Use antiemetics even when nausea is present without vomiting, as nausea itself is highly disabling 1
  • Give antiemetics 20-30 minutes before NSAIDs for synergistic analgesia 1

Emergency Department/Urgent Care IV Treatment

The optimal IV cocktail is metoclopramide 10 mg IV + ketorolac 30 mg IV, providing rapid pain relief while minimizing rebound headache risk. 1

IV Treatment Components

  • Ketorolac 30 mg IV (or 60 mg IM if <65 years old): Rapid onset with 6-hour duration 1
  • Metoclopramide 10 mg IV: Provides both antiemetic and direct analgesic effects 1
  • Alternative: Prochlorperazine 10 mg IV is comparable in efficacy to metoclopramide 1
  • Second-line: Dihydroergotamine (DHE) IV or intranasal for refractory cases 1

What NOT to Use

  • Avoid opioids (including hydromorphone) as they lead to dependency, rebound headaches, and loss of efficacy 1
  • Avoid butalbital-containing compounds due to high risk of medication-overuse headache 1
  • Prednisone has limited evidence for acute migraine and is more appropriate for status migrainosus 1

Critical Frequency Limitation

Limit ALL acute migraine medications to no more than 2 days per week to prevent medication-overuse headache (MOH). 1

  • Using acute medications >2 days/week leads to increasing headache frequency and potentially daily headaches 1
  • NSAIDs trigger MOH at ≥15 days/month 1
  • Triptans trigger MOH at ≥10 days/month 1
  • If patients need acute treatment more frequently, immediately initiate preventive therapy 1, 4

When to Initiate Preventive Therapy

Preventive therapy is indicated when: 4

  • ≥2 migraine attacks per month producing disability lasting ≥3 days 4
  • Using abortive medication more than twice per week 4
  • Contraindication to or failure of acute treatments 4
  • Presence of uncommon migraine conditions (hemiplegic migraine, prolonged aura, migrainous infarction) 4

First-Line Preventive Medications

  • Propranolol 80-240 mg/day (strongest evidence) 4
  • Timolol 20-30 mg/day 4
  • Topiramate 100 mg/day (typically 50 mg twice daily) 4
  • Candesartan (particularly useful with comorbid hypertension) 4

Second-Line Preventive Medications

  • Amitriptyline 30-150 mg/day (especially for mixed migraine and tension-type headache) 4
  • Valproate 800-1500 mg/day or divalproex sodium 500-1500 mg/day (strictly contraindicated in women of childbearing potential due to teratogenic effects) 4

Third-Line: CGRP Monoclonal Antibodies

  • Erenumab, fremanezumab, galcanezumab, or eptinezumab when first- and second-line options fail 4
  • Assess efficacy only after 3-6 months of treatment 4

Contraindications to Triptans

Triptans are contraindicated in: 1, 2

  • Ischemic heart disease or previous myocardial infarction 1
  • Uncontrolled hypertension 1
  • Basilar or hemiplegic migraine 2
  • Vasospastic coronary disease 1
  • Significant cardiovascular disease 1

Common Pitfalls to Avoid

  • Delaying treatment: Triptans work best when taken early while pain is still mild 1
  • Monotherapy when combination is superior: Always consider triptan + NSAID combination for moderate-to-severe attacks 1
  • Ignoring medication-overuse headache: Failure to recognize frequent acute medication use (>2 days/week) perpetuates the problem 1
  • Using opioids routinely: This leads to dependency and worsening headache patterns 1
  • Inadequate preventive trial duration: Preventive medications require 2-3 months for oral agents before assessing efficacy 4
  • Wrong route selection: Oral medications are ineffective when significant nausea/vomiting is present 1, 2

References

Guideline

Acute Headache Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Management of Migraines in the Emergency Room

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Migraine Prevention Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.